Nemluvio was well tolerated and showed sustained improvements in moderate to severe prurigo nodularis during a 2-year ...

Galderma Initiates Two New Clinical Trials Investigating Nemolizumab in Patients With Systemic Sclerosis and Chronic Pruritus of Unknown Origin ...

Prurigo nodularis (PN) is a chronic inflammatory skin disease characterized by intense itch and thickened red bumps on the arms, legs and trunk. 1 Due to the result of persistent, intense ...

Subjects in the trial saw clearance or near-clearance of skin nodules, as measured by the Investigator’s Global Assessment score.

Sanofi SNY and its partner, Regeneron REGN, announced that the FDA has approved their blockbuster medicine, Dupixent (dupilumab), for the treatment of adult patients with bullous pemphigoid (BP), a ...

Sanofi and Regeneron are committed to helping patients in the US who are prescribed Dupixent gain access to the medicine and receive the support they may need with the DUPIXENT MyWay® program. For ...

Regeneron and Sanofi are committed to helping patients in the U.S. who are prescribed Dupixent gain access to the medicine and receive the support they may need with the DUPIXENT MyWay® program. For ...

LONDON, GREATER LONDON, UNITED KINGDOM, June 19, 2025 /EINPresswire.com/ -- The Business Research Company’s Latest Report Explores Market Driver, Trends, Regional Insights - Market Sizing & Forecasts ...

Galderma’s Nemluvio (nemolizumab) has demonstrated sustained and clinically meaningful improvements in the key signs and ...

The global market for prurigo nodularis treatment has witnessed substantial growth in recent years and is projected to grow from $1.64 billion in 2024 to $1.73 billion in 2025 at a compound annual ...

Nemolizumab was well tolerated in the long-term treatment of prurigo nodularis, and this study identified no new safety signals. These results follow data from the ARCADIA (NCT03989206) long-term ...